Aliskiren

Identification

Summary

Aliskiren is a direct renin inhibitor used to manage hypertension.

Brand Names

Rasilez, Tekturna, Tekturna Hct

Generic Name

Aliskiren

DrugBank Accession Number

DB09026

Background

Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension.⁵ It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.¹⁰ Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.⁵

Type

Small Molecule

Groups

Approved, Investigational

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Aliskiren (DB09026)

×

Close

Weight

Average: 551.7583
Monoisotopic: 551.393436443

Chemical Formula

C₃₀H₅₃N₃O₆

Synonyms

• Aliskiren
• Aliskireno

External IDs

• CGP 60536
• CGP60536B
• SPP 100
• SPP100

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Aliskiren is used for the treatment of hypertension in children above 6 years and adults.⁹ This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.^12,13

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Used in combination to manage	Hypertension	Combination Product in combination with: Amlodipine (DB00381)	••••••••••••			••••••
Management of	Hypertension		••••••••••••	••••••••••• •••••• ••••••••		••••••• ••••••
Used in combination to manage	Hypertension	Combination Product in combination with: Hydrochlorothiazide (DB00999)	••••••••••••		••• •••••••••• •••••••••• •••• •••••••••••	••••••

Create Account

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Aliskiren reduces blood pressure by inhibiting renin. This leads to a cascade of events that decreases blood pressure, lowering the risk of fatal and nonfatal cardiovascular events including stroke and myocardial infarction.^2,9

Mechanism of action

Aliskiren is a renin inhibitor.⁹ Renin is secreted by the kidneys when blood volume and renal perfusion decrease. It normally cleaves the protein angiotensinogen to form angiotensin I. Angiotensin I is then converted to angiotensin II, an active protein. Angiotensin II is a potent vasoconstrictor that causes the release of catecholamines into the circulation. It also promotes the secretion of aldosterone in addition to sodium reabsorption, increasing blood pressure. Additionally, angiotensin II acts on the adrenal cortex where it stimulates aldosterone release. Aldosterone increases sodium reabsorption and potassium excretion in the nephron. ¹¹

Aliskiren prevents the above process via binding to renin at its active site, stopping the cleavage of angiotensin, in turn inhibiting the formation of angiotensin I. This ends the cascade of angiotensin II mediated mechanisms that normally increase blood pressure.⁵

Target	Actions	Organism
ARenin	inhibitor	Humans

Absorption

Aliskiren is absorbed in the gastrointestinal tract and is poorly absorbed with a bioavailability between 2.0 and 2.5%.^6,9 Peak plasma concentrations of aliskiren are achieved between 1 to 3 hours after administration.^6,9 Steady-state concentrations of aliskiren are achieved within 7-8 days of regular administration.¹

Volume of distribution

Unchanged aliskiren accounts for about 80% of the drug found in the plasma.^7,9

Protein binding

The plasma protein binding of aliskiren ranges from 47-51%.^1,6

Metabolism

About 80% of the drug in plasma following oral administration is unchanged. Two major metabolites account for about 1-3% of aliskiren in the plasma. One metabolite is an O-demethylated alcohol derivative and the other is a carboxylic acid derivative. Minor oxidized and hydrolyzed metabolites may also be found in the plasma.^7,9

Route of elimination

Aliskiren is mainly excreted via the hepatobiliary route and by oxidative metabolism by hepatic cytochrome enzymes.¹ Approximately one-quarter of the absorbed dose appears in the urine as unchanged parent drug. ⁹ One pharmacokinetic study of radiolabeled aliskiren detected 0.6% radioactivity in the urine and more than 80% in the feces, suggesting that aliskiren is mainly eliminated by the fecal route.⁷

Half-life

Plasma half-life for aliskiren can range from 30 to 40 hours ⁷ with an accumulation half-life of about 24 hours.⁷

Clearance

Aliskiren is partially cleared in the kidneys, and safety data have not been established for patients with a creatinine clearance of less than 30 mL/min.⁹ One pharmacokinetic study revealed an average renal clearance of 1280 +/- 500 mL/hour in healthy volunteers.⁸

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

The oral LD50 of aliskiren in rats is >2000 mg/kg.¹⁴ Overdose information is limited in the literature, however, an overdose with aliskiren is likely to result in hypotension. Supportive treatment should be initiated in the case of an overdose.^9,15

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abaloparatide	The risk or severity of adverse effects can be increased when Abaloparatide is combined with Aliskiren.
Abametapir	The serum concentration of Aliskiren can be increased when it is combined with Abametapir.
Acebutolol	Acebutolol may increase the hypotensive activities of Aliskiren.
Aceclofenac	The risk or severity of renal failure and hypertension can be increased when Aceclofenac is combined with Aliskiren.
Acemetacin	The risk or severity of renal failure and hypertension can be increased when Acemetacin is combined with Aliskiren.

Food Interactions

• Do not take with or immediately after a high-fat meal. The absorption of aliskiren is substantially reduced by taking it with high-fat meals.
• Take with or without food. Take consistently at the same time in regard to meals.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Aliskiren hemifumarate	C8A0P8G029	173334-58-2	KLRSDBSKUSSCGU-KRQUFFFQSA-N

Product Images

PreviousNext

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Rasilez	Tablet, film coated	300 mg	Oral	Noden Pharma Dac	2016-09-08	Not applicable
Rasilez	Tablet, film coated	150 mg	Oral	Noden Pharma Dac	2016-09-08	Not applicable
Rasilez	Tablet, film coated	300 mg	Oral	Noden Pharma Dac	2016-09-08	Not applicable
Rasilez	Tablet, film coated	300 mg	Oral	Noden Pharma Dac	2016-09-08	Not applicable
Rasilez	Tablet, film coated	150 mg	Oral	Noden Pharma Dac	2016-09-08	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Aliskiren	Tablet, film coated	150 mg/1	Oral	Par Pharmaceutical, Inc.	2019-03-25	Not applicable
Aliskiren	Tablet, film coated	300 mg/1	Oral	Prasco Laboratories	2019-03-04	Not applicable
Aliskiren	Tablet, film coated	300 mg/1	Oral	Par Pharmaceutical, Inc.	2019-03-25	Not applicable
Aliskiren	Tablet, film coated	150 mg/1	Oral	Prasco Laboratories	2019-03-04	Not applicable
Sandoz Aliskiren	Tablet	150 mg	Oral	Sandoz Canada Incorporated	Not applicable	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Amturnide	Aliskiren hemifumarate (300 mg/1) + Amlodipine besylate (5 mg/1) + Hydrochlorothiazide (25 mg/1)	Tablet, film coated	Oral	Novartis	2010-12-21	2016-03-31
Amturnide	Aliskiren hemifumarate (300 mg/1) + Amlodipine besylate (10 mg/1) + Hydrochlorothiazide (25 mg/1)	Tablet, film coated	Oral	Novartis	2010-12-21	2016-01-31
Amturnide	Aliskiren hemifumarate (300 mg/1) + Amlodipine besylate (5 mg/1) + Hydrochlorothiazide (12.5 mg/1)	Tablet, film coated	Oral	Novartis	2010-12-21	2016-01-31
Amturnide	Aliskiren hemifumarate (300 mg/1) + Amlodipine besylate (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)	Tablet, film coated	Oral	Novartis	2010-12-21	2015-10-31
Amturnide	Aliskiren hemifumarate (150 mg/1) + Amlodipine besylate (5 mg/1) + Hydrochlorothiazide (12.5 mg/1)	Tablet, film coated	Oral	Novartis	2010-12-21	2015-09-30

Categories

ATC Codes

C09XA54 — Aliskiren, amlodipine and hydrochlorothiazide

• C09XA — Renin-inhibitors
• C09X — OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

C09XA53 — Aliskiren and amlodipine

• C09XA — Renin-inhibitors
• C09X — OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

C09DX02 — Valsartan and aliskiren

• C09DX — Angiotensin II receptor blockers (ARBs), other combinations
• C09D — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

C09XA02 — Aliskiren

• C09XA — Renin-inhibitors
• C09X — OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

C09XA52 — Aliskiren and hydrochlorothiazide

• C09XA — Renin-inhibitors
• C09X — OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

Drug Categories

• Acids, Acyclic
• Agents Acting on the Renin-Angiotensin System
• Agents causing hyperkalemia
• Antihypertensive Agents
• Antihypertensive Agents Indicated for Hypertension
• Benzene Derivatives
• Cytochrome P-450 CYP3A Substrates
• Cytochrome P-450 CYP3A4 Substrates
• Cytochrome P-450 Substrates
• Dicarboxylic Acids
• Enzyme Inhibitors
• Ethers
• Hypotensive Agents
• Methyl Ethers
• P-glycoprotein substrates
• Protease Inhibitors
• Renin Inhibitors

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as delta amino acids and derivatives. These are compounds containing a carboxylic acid group and an amino group at the C5 carbon atom.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Delta amino acids and derivatives

Alternative Parents

Beta amino acids and derivatives / Phenylbutylamines / Anisoles / Methoxybenzenes / Phenoxy compounds / Alkyl aryl ethers / Aralkylamines / N-acyl amines / Secondary carboxylic acid amides / 1,2-aminoalcohols / Secondary alcohols / Primary carboxylic acid amides / Dialkyl ethers / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds

show 8 more

Substituents

1,2-aminoalcohol / Alcohol / Alkyl aryl ether / Amine / Anisole / Aralkylamine / Aromatic homomonocyclic compound / Benzenoid / Beta amino acid or derivatives / Carbonyl group / Carboxamide group / Delta amino acid or derivatives / Dialkyl ether / Ether / Fatty acyl / Fatty amide / Hydrocarbon derivative / Methoxybenzene / Monocyclic benzene moiety / N-acyl-amine / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Phenol ether / Phenoxy compound / Phenylbutylamine / Primary aliphatic amine / Primary amine / Primary carboxylic acid amide / Secondary alcohol / Secondary carboxylic acid amide

show 24 more

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

monocarboxylic acid amide, monomethoxybenzene (CHEBI:601027)

Affected organisms

• Humans and other mammals

Chemical Identifiers

UNII

502FWN4Q32

CAS number

173334-57-1

InChI Key

UXOWGYHJODZGMF-QORCZRPOSA-N

InChI

InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1

IUPAC Name

(2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide

SMILES

COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1

References

Synthesis Reference

Hanessian S, Guesné S, Chénard E. Total synthesis of "aliskiren": the first Renin inhibitor in clinical practice for hypertension. Org Lett. 2010;12(8):1816‐1819. doi:10.1021/ol100427v

General References

1. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP: Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31. [Article]
2. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005 Mar 1;111(8):1012-8. Epub 2005 Feb 21. [Article]
3. Staessen JA, Li Y, Richart T: Oral renin inhibitors. Lancet. 2006 Oct 21;368(9545):1449-56. [Article]
4. Sanoski CA: Aliskiren: an oral direct renin inhibitor for the treatment of hypertension. Pharmacotherapy. 2009 Feb;29(2):193-212. doi: 10.1592/phco.29.2.193. [Article]
5. Oh BH: Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives. Expert Opin Pharmacother. 2007 Nov;8(16):2839-49. doi: 10.1517/14656566.8.16.2839. [Article]
6. Buczko W, Hermanowicz JM: Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep. 2008 Sep-Oct;60(5):623-31. [Article]
7. Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, Valencia J, Riviere GJ, End P, Vaidyanathan S: Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos. 2007 Aug;35(8):1418-28. doi: 10.1124/dmd.106.013797. Epub 2007 May 17. [Article]
8. Vaidyanathan S, Bigler H, Yeh C, Bizot MN, Dieterich HA, Howard D, Dole WP: Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet. 2007;46(8):661-75. doi: 10.2165/00003088-200746080-00003. [Article]
9. FDA Approved Products: Tekturna (Aliskiren) oral tablets and pellets [Link]
10. The Pharmaletter: Novartis and Speedel [Link]
11. NIH StatPearls: Physiology, Renin Angiotensin System [Link]
12. FDA Approved Products: Tekamlo (amlodipine and aliskiren) oral tablets [Link]
13. FDA Approved Products: Tekturna HCT (aliskiren and hydrochlorothiazide) oral tablets [Link]
14. Product monograph: Rasilez HCT (Aliskiren fumarate and hydrochlorothiazide oral tablets) [Link]
15. NIH StatPearls: Aliskiren [Link]

External Links

Human Metabolome Database

HMDB0015387

KEGG Drug

D03208

PubChem Compound

5493444

PubChem Substance

310264980

ChemSpider

4591452

BindingDB

17950

RxNav

325646

ChEBI

601027

ChEMBL

CHEMBL1639

ZINC

ZINC000004393164

PharmGKB

PA143487910

PDBe Ligand

C41

Drugs.com

Drugs.com Drug Page

Wikipedia

Aliskiren

PDB Entries

2v0z

FDA label

Download (612 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Completed	Not Available	Type 2 Diabetes Mellitus	1
4	Completed	Diagnostic	Hypertension	1
4	Completed	Other	Coronary Artery Disease (CAD) / Type 2 Diabetes Mellitus	1
4	Completed	Screening	Chronic Kidney Disease (CKD) / Hypertension / Proteinuria	1
4	Completed	Treatment	Blood Pressures / Chronic Kidney Disease (CKD) / Proteinuria	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Tablet, film coated	Oral
Tablet, film coated	Oral	150 MG
Tablet, film coated	Oral	300 MG
Tablet	Oral
Tablet	Oral	150 mg
Tablet	Oral	300 mg
Tablet, film coated	Oral	150 mg/1
Tablet, film coated	Oral	300 mg/1
Tablet, film coated	Oral

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
CA2147056	No	2005-10-25	2015-04-13
US5559111	Yes	1996-09-24	2019-01-21
US8617595	Yes	2013-12-31	2026-08-19
US8618172	No	2013-12-31	2028-07-13
US8168616	No	2012-05-01	2026-07-03
US8613949	No	2013-12-24	2029-12-21
US8618174	No	2013-12-31	2021-11-15
US8183295	No	2012-05-22	2023-05-16
US9023893	No	2015-05-05	2022-03-03

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	>95	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022545Orig1s000EA.pdf
boiling point (°C)	748.4±60.0	https://m.chemicalbook.com/ChemicalProductProperty_EN_CB9966226.htm
water solubility	Highly soluble in water (as hemifumarate salt)	Not Available
logP	2.45	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103912/
pKa	9.49	https://m.chemicalbook.com/ChemicalProductProperty_EN_CB9966226.htm

Predicted Properties

Property	Value	Source
Water Solubility	0.0021 mg/mL	ALOGPS
logP	3.87	ALOGPS
logP	3.12	Chemaxon
logS	-5.4	ALOGPS
pKa (Strongest Acidic)	14.56	Chemaxon
pKa (Strongest Basic)	9.57	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	7	Chemaxon
Hydrogen Donor Count	4	Chemaxon
Polar Surface Area	146.13 Å2	Chemaxon
Rotatable Bond Count	19	Chemaxon
Refractivity	154.32 m3·mol-1	Chemaxon
Polarizability	63.28 Å3	Chemaxon
Number of Rings	1	Chemaxon
Bioavailability	0	Chemaxon
Rule of Five	No	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-001c-6393230000-97b551a81f81203eb590
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-0uxr-0700090000-7a3148e765b056fbdbb2
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-014i-3901100000-cb596bd3c4d4c9e1c01f
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-00kr-7911000000-f660df43e70edac0517a
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-0079-5910000000-d3e40bdba155982e7e43
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-00dr-3900000000-8bce7f74c2390532741c
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-00di-3900000000-12d8e1ded46f53c83764
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0019-0000950000-e45c32fa4cac95668993
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0v4i-4920100000-82dc644fa438b541d394
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0fk9-9810000000-c1c9bdda4686e3e603b1
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0udi-3900000000-f5052afca313a2f0c68b
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0f9f-7900000000-12cc981f01c6cad986b8
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0006-9300000000-a3026b636a234fc9ae1f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0gb9-0200590000-4ad109603a6b610b1065
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-004i-0291460000-a7b1a433f03788c72107
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-01qi-0009600000-8a93475868455e81179e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0006-6249480000-2a3f8daecdfbe6ef352b
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-05mo-1007900000-6a0f017df33b43ecc071
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-054o-7339430000-456f2b7247a438959a62

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	271.6406298	predicted	DarkChem Lite v0.1.0
[M-H]-	236.74153	predicted	DeepCCS 1.0 (2019)
[M+H]+	271.0560298	predicted	DarkChem Lite v0.1.0
[M+H]+	238.56642	predicted	DeepCCS 1.0 (2019)
[M+Na]+	270.8682298	predicted	DarkChem Lite v0.1.0
[M+Na]+	244.17224	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	0.6	N/A	N/A	A29605 / A29606 / A29608 / A29609 / A29611
IC 50 (nM)	0.53	N/A	N/A	A29607
IC 50 (nM)	0.65	N/A	N/A	A29607
IC 50 (nM)	2.21	N/A	N/A	A29610

Details

Binding Properties1. Renin

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Inhibitor

General Function

Receptor binding

Specific Function

Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of b...

Gene Name

REN

Uniprot ID

P00797

Uniprot Name

Renin

Molecular Weight

45057.125 Da

References

1. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002 Jan;39(1):E1-8. [Article]
2. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, Ruger H, Goschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003 Sep 5;308(4):698-705. [Article]
3. Menard J, Guyene TT, Peyrard S, Azizi M: Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens. 2006 Mar;24(3):529-34. [Article]
4. Azizi M, Webb R, Nussberger J, Hollenberg NK: Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006 Feb;24(2):243-56. [Article]
5. Gradman AH, Vivas Y: New drugs for hypertension: what do they offer? Curr Hypertens Rep. 2006 Oct;8(5):425-32. [Article]
6. Wal P, Wal A, Rai AK, Dixit A: Aliskiren: An orally active renin inhibitor. J Pharm Bioallied Sci. 2011 Apr;3(2):189-93. doi: 10.4103/0975-7406.80764. [Article]
7. FDA Approved Products: Tekturna (Aliskiren) oral tablets and pellets [Link]

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at October 13, 2014 22:29 / Updated at February 20, 2024 23:55